Currently, there are two FDA-approved anti-fibrotic drugs to treat IPF: Nintedanib, a tyrosine-kinase inhibitor, and Pirfenidone, an inhibitor of pro-fibrotic growth factors and collagens), both of which target TGFβ signaling. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.